Ferroptosis: Insight into the Treatment of Hepatocellular Carcinoma

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2024 Nov 13

PMID 39538215

Authors

Chuanjie Liao

Youwu He

Xinning Luo

Ganlu Deng

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignances in the world, with high morbidity and mortality. Due to the hidden onset of symptoms, there are huge obstacles in early diagnosis, recurrence, metastasis and drug resistance. Although great strides have been made in the treatment of HCC, effective treatment options are still limited and achieving longer survival for patients remains urgent. Ferroptosis is a novel type of programmed cell death that is mainly caused by iron-dependent oxidative damage. With further investigations, ferroptosis has been proved to be associated with the occurrence and development of various tumors. This article reviews the regulatory mechanism and signal transduction pathways of ferroptosis, investigates the complex relationship between autophagy, sorafenib resistance and immunotherapy with ferroptosis involved in HCC, providing new ideas and directions for the treatment of HCC.

Citing Articles

Recent updates of centromere proteins in hepatocellular carcinoma: a review.

Yang Z, Chen W, Liu Y, Niu Y Infect Agent Cancer. 2025; 20(1):7.

PMID: 39915786 PMC: 11800463. DOI: 10.1186/s13027-024-00630-2.

References

Chen Q, Zheng W, Guan J, Liu H, Dan Y, Zhu L . SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ. 2022; 30(1):137-151. PMC: 9883449. DOI: 10.1038/s41418-022-01051-7. View

Lai Y, Han X, Xie B, Xu Y, Yang Z, Wang D . EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2. Cancer Sci. 2024; 115(7):2220-2234. PMC: 11247551. DOI: 10.1111/cas.16186. View

Zou Y, Sun Z, Sun S . LncRNA HCG18 contributes to the progression of hepatocellular carcinoma via miR-214-3p/CENPM axis. J Biochem. 2020; 168(5):535-546. DOI: 10.1093/jb/mvaa073. View

Tang J, Long G, Hu K, Xiao D, Liu S, Xiao L . Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT. Adv Sci (Weinh). 2023; 10(33):e2302953. PMC: 10667802. DOI: 10.1002/advs.202302953. View

Chen S, Xia H, Sheng L . WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability. Dig Liver Dis. 2022; 55(7):967-981. DOI: 10.1016/j.dld.2022.12.005. View

Santana-Codina N, Gikandi A, Mancias J . The Role of NCOA4-Mediated Ferritinophagy in Ferroptosis. Adv Exp Med Biol. 2021; 1301:41-57. DOI: 10.1007/978-3-030-62026-4_4. View

Lyu N, Zeng Y, Kong Y, Chen Q, Deng H, Ou S . Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis. Ann Transl Med. 2021; 9(8):675. PMC: 8106082. DOI: 10.21037/atm-21-997. View

Li X, Li Y, Lian P, Lv Q, Liu F . Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma. Hum Exp Toxicol. 2023; 42:9603271221142818. DOI: 10.1177/09603271221142818. View

Bartolini D, Dallaglio K, Torquato P, Piroddi M, Galli F . Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma. Transl Res. 2017; 193:54-71. DOI: 10.1016/j.trsl.2017.11.007. View

10.

Lu M, Lu L, Dong Q, Yu G, Chen J, Qin L . Elevated G6PD expression contributes to migration and invasion of hepatocellular carcinoma cells by inducing epithelial-mesenchymal transition. Acta Biochim Biophys Sin (Shanghai). 2018; 50(4):370-380. DOI: 10.1093/abbs/gmy009. View

11.

Gunassekaran G, Vadevoo S, Baek M, Lee B . M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021; 278:121137. DOI: 10.1016/j.biomaterials.2021.121137. View

12.

Lu Y, Chan Y, Tan H, Zhang C, Guo W, Xu Y . Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2022; 41(1):3. PMC: 8722264. DOI: 10.1186/s13046-021-02208-x. View

13.

Wang Z, Li M, Liu Y, Qiao Z, Bai T, Yang L . Dihydroartemisinin triggers ferroptosis in primary liver cancer cells by promoting and unfolded protein response‑induced upregulation of CHAC1 expression. Oncol Rep. 2021; 46(5). PMC: 8485000. DOI: 10.3892/or.2021.8191. View

14.

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View

15.

Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E . Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol. 2021; 43:102006. PMC: 8163990. DOI: 10.1016/j.redox.2021.102006. View

16.

Chen Y, Li L, Lan J, Cui Y, Rao X, Zhao J . CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma. Mol Cancer. 2022; 21(1):11. PMC: 8725338. DOI: 10.1186/s12943-021-01466-9. View

17.

Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R . Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2015; 63(1):173-84. PMC: 4688087. DOI: 10.1002/hep.28251. View

18.

Wang S, Zhu L, Li T, Lin X, Zheng Y, Xu D . Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma. Cell Rep Med. 2024; 5(2):101415. PMC: 10897610. DOI: 10.1016/j.xcrm.2024.101415. View

19.

Wang X, Liang Q, Zhang L, Gou H, Li Z, Chen H . C8orf76 Promotes Gastric Tumorigenicity and Metastasis by Directly Inducing lncRNA DUSP5P1 and Associates with Patient Outcomes. Clin Cancer Res. 2019; 25(10):3128-3140. DOI: 10.1158/1078-0432.CCR-18-2804. View

20.

Li J, Liu J, Zhou Z, Wu R, Chen X, Yu C . Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023; 15(720):eadg3049. DOI: 10.1126/scitranslmed.adg3049. View